Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Zhu, Hong ^a   Yang, Wei ^a   He, Ling juan ^a   Ding, Wan jing ^a   Zheng, Lin ^a   Liao, Si da ^a   Huang, Ping ^b   Lu, Wei ^c   He, Qiao jun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Tongde hospital of Zhejiang province   (China)

^c EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ACTIVATING TRANSCRIPTION FACTOR 4; BIM PROTEIN; CASPASE 3; CELASTROL; CYTOCHROME C; INITIATION FACTOR 2ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN BEL 7402; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME RELEASE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRION; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNOPRECIPITATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SULFONAMIDES; TRITERPENES;

EID: 84871424648     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052333     Document Type: Article

References (39)

1. Jayanthan A, Incoronato A, Singh A, Blackmore C, Bernoux D, et al. (2011) Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Pediatr Blood Cancer 56: 353-360.
2. Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, et al. (2012) Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett 317: 218-225.
3. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, et al. (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68: 2321-2328.
4. Meynet O, Bénéteau M, Jacquin MA, Pradelli LA, Cornille A, et al. (2012) Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 26: 1145-1147.
5. Zheng L, Yang W, Zhang C, Ding WJ, Zhu H, et al. (2011) GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett 309: 27-36.
6. Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, et al. (2011) Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther 10: 1264-1275.
7. Chen S, Dai Y, Harada H, Dent P, Grant S, (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 782-791.
8. Adams JM, S Cory, (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337.
9. Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, et al. (2012) Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 18: 783-795.
10. Okumura K, Huang S, Sinicrope FA, (2008) Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res 14: 8132-8142.
11. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, et al. (2012) Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res 18: 487-498.
12. Raats DA, de Bruijn MT, Steller EJ, Emmink BL, Borel-Rinkes IH, et al. (2011) Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737. Cell Oncol (Dordr) 34: 307-313.
13. Dai Y, Desano J, Tang W, Meng X, Meng Y, et al. (2010) Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 5: e14153.
14. Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, et al. (2010) Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest 28: 23-32.
15. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, et al. (2009) Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 284: 35381-35389.
16. Sreeramulu S, Gande SL, Göbel M, Schwalbe H, et al. (2009) Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 48: 5853-5855.
17. Wang WB, Feng LX, Yue QX, Wu WY, Guan SH, et al. (2012) Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J Cell Physiol 227: 2196-2206.
18. Fleischer B, Schulze-Bergkamen H, Schuchmann M, Weber A, Biesterfeld S, et al. (2006) Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol. 28: 25-32.
19. Fernández Y, Verhaegen M, Miller TP, Rush JL, Steiner P, et al. (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65: 6294-6304.
20. Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, et al. (2009) Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 124: 1990-1996.
21. Zhang J, Cao J, Weng Q, Wu R, Yan Y, et al. (2010) Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway. PLoS One 5: e13910.
22. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293.
23. Averous J, Bruhat A, Jousse C, Carraro V, Thiel G, et al. (2004) Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation. J Biol Chem 279: 5288-5297.
24. Chou TC, P Talalay, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
25. Rosen A, L Casciola-Rosen, (1997) Macromolecular substrates for the ICE-like proteases during apoptosis. J Cell Biochem 64: 50-54.
26. Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H, (1999) Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene 18: 5703-5713.
27. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330.
28. Peng B, Xu L, Cao F, Wei T, Yang C, et al. (2010) HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer 16 9: 79.
29. Zhang R, Luo D, Miao R, Bai L, Ge Q, et al. (2005) Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24: 3954-3963.
30. Taiyab A, Sreedhar AS, Rao ChM, (2009) Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochem Pharmacol 78: 142-152.
31. Patterson J, Palombella VJ, Fritz C, Normant E, (2008) IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 61: 923-932.
32. Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CP, (2010) Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J Biol Chem 285: 6091-6100.
33. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, et al. (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 52: 1310-1321.
34. Kang MH, C.P Reynolds, (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126-1132.
35. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, et al. (2007) Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A 104: 6217-6222.
36. Yang H, Chen D, Cui QC, Yuan X, Dou QP, (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
37. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 104: 19488-19493.
38. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293.
39. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, et al. (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 106: 2200-2205.